Romosozumab-aqqg (Evenity)

Evenity (romosozumab-aqqg) is covered only for postmenopausal women with osteoporosis at high risk for fracture per the FDA label (uses outside the FDA‑approved indication are not covered). Approval (12 months) requires documentation of BOTH a disease‑severity criterion (T‑score ≤ −2.5, an osteoporotic/fragility fracture, or low bone mass with high fracture risk) AND a prior‑therapy/intolerance or qualifying clinical condition (e.g., inadequate response after a 12‑month oral bisphosphonate trial, intolerance or inability to take oral bisphosphonates, prior IV bisphosphonate, or severe renal impairment/CKD), with dosing per the 210 mg monthly subcutaneous regimen.

"Evenity is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk for fracture; or patients w..."